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mel-18 Negatively Regulates Cell Cycle Progression
upon B Cell Antigen Receptor Stimulation
through a Cascade Leading to c-myc/cdc25
mel-18 and bmi-1 are thought to correspond to Posterior
sex comb (Psc), M33 to Polycomb (Pc), rae-28 /Mph-1
and Hph2 to polyhomeotic (ph), ENX-1 to Enhancer of
zeste [E(z)], and eed to extra sex combs (esc) (Tagawa
et al., 1990; Brunk et al., 1991; van Lohuizen et al., 1991;
Osamu Tetsu,* Hiroto Ishihara,³ Rieko Kanno,*³
Masaya Kamiyasu,³ Hiroko Inoue,³ Takeshi Tokuhisa,²
Masaru Taniguchi,* and Masamoto Kanno*³§
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Pearce et al., 1992; Ishida et al., 1993; Nomura et al.,Chiba University and CREST (Core Research for
1994; Hobert et al., 1996; Schumacher et al., 1996; Al-Evolutional Science and Technology) of Japan
kema et al., 1997). These mammalian PcG genes areScience and Technology Corporation
also known to be involved in the regulation of homeotic²Department of Developmental Genetics
genes (van der Lugt et al., 1994, 1996; Akasaka et al.,Graduate School of Medicine
1996; Core et al., 1997).Chiba University
As described previously, the mel-18 gene productChiba 260-8670
binds DNA specifically to the sequence 59-GACTNGJapan
ACT-39 despite its low affinity and suppresses the activ-³Department of Immunology and Parasitology
ity of a juxtaposed enhancer element in vitro. Interest-School of Medicine
ingly, this binding sequence is found within the regula-Hiroshima University
tory region of various genes, including not only HoxHiroshima 734-8551
genes but also c-myc and bcl-2 genes, etc., suggestingJapan
diverse functions of mel-18 as a mammalian PcG gene
(Kanno et al., 1995). In fact, mel-18 seems to be a tumor
suppressor gene, because the inhibition of endogenousSummary
mel-18 expression by antisense RNA in NIH 3T3 cells
causes solid tumors when transplanted into nude mice
mel-18 is a mammalian Polycomb group gene encod-
(Kanno et al., 1995). As for the other PcG genes, bmi-1,
ing a transcriptional repressor with tumor suppressive
a closely related mel-18 homolog, has been demon-
activity. Overexpression of mel-18 in mice results in
strated to be an oncogene (Haupt et al., 1993). Also,
cell cycle arrest of B cells upon B cell receptor stimula- a direct molecular interaction between ENX-1 and the
tion with downregulation of c-myc. This phenotype protooncogene product Vav has been demonstrated.
is rescued in mel-18/c-myc double-transgenic mice, Furthermore, the Drosophila PcG gene multi sex combs
suggesting that c-myc locates downstream of mel- (mxc) regulates cell growth as a tumor suppressor (San-
18. In mel-18 transgenic mice, the downregulation of tamaria and Randsholt, 1995) and sex comb on midleg
cyclins D2 and E; CDK4, -6, and -7; and CDC25A causes (Scm) exhibits homology in multiple domains to a Dro-
the impairment in the activities of cyclin-dependent sophila tumor suppressor protein, the product of the
kinases, resulting in hypophosphorylation of the reti- lethal(3) malignant brain tumor gene (Wismar et al.,
noblastoma protein. In contrast, the upregulation of 1995; Bornemann et al., 1996). These findings suggest
c-Myc, CDC25, and CDC2/CDK2 kinase activities re- the involvement of PcG genes in the regulation of normal
sults in the augmentation of B cell proliferation in mel- and abnormal cell growth; however, the issue of how
18-deficient mice. We therefore propose that mel-18 they work remains largely unclear.
negatively regulates the cell cycle through a c-myc/ Recently, we and others have demonstrated that the
cdc25 cascade. mammalian PcG genes regulate the growth and differen-
tiation of lymphoid cells. For example, the targeted dele-
Introduction tion of mel-18 and also bmi-1 results not only in posterior
transformation of the axial skelton due to an anterior
The Polycomb group (PcG) genes were originally identi- shift in the expression of Hox genes, but also severe
fied in Drosophila as components required for the long- hypoplasia in the lymphoid system due to insufficient
term repression of homeotic genes (Simon, 1995; Zink response to IL-7 stimulation of the lymphoid precursors
and Paro, 1995). In Drosophila embryos with mutated (van der Lugt et al., 1994, 1996; Akasaka et al., 1996,
PcG genes, the expression of homeotic genes starts 1997). IL-7 responsiveness of lymphocyte precursors is
correctly but subsequently spreads beyond normal thought to be conferred by the expression of signal
boundaries, as characterized by posterior homeotic transducing molecules located downstream of the IL-7
transformation (Struhl and Akam, 1985; White and Wil- receptor a chain and by the expression and activation
cox, 1985; Wedeen et al., 1986; Celniker et al., 1990; of molecules required for cell cycle progression as well
Soto et al., 1995). Thus, PcG genes are part of a cellular as for cell survival (Akasaka et al., 1997; Maraskovsky
memory system that is responsible for the stable trans- et al., 1997). Thus, it seems worthwhile to investigate the
mission of gene activity to progeny cells. role of mel-18 in the cell cycle regulation of lymphocytes.
Mammalian homologs of PcG genes have recently We found that overexpression of mel-18 in mice causes
been identified. Based on their structural similarities, cell cycle arrest of B cells upon B cell receptor stimula-
tion accompanied by the downregulation of c-myc ex-
pression. This phenotype was rescued by enforced ex-§ To whom correspondence should be addressed (e-mail: kanno@
mcai.med.hiroshima-u.ac.jp). pression of c-myc in mel-18/c-myc double-transgenic
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mice, suggesting that the c-myc gene locates down- lipopolysaccharide (LPS) and [3H]thymidine incorpora-
tion was measured. Surprisingly, more than 90% sup-stream of mel-18. The regulation of cell cycle progres-
sion depends on the sequential activation of a series of pression of thymidine uptake was observed with anti-
IgM stimulation, while only 10%±20% suppression wascyclin-dependent kinases (CDKs), which become cata-
lytically active or inactive in response to a variety of detected 3 days after LPS stimulation (Figure 1D). We
then performed a kinetic study of proliferation from daysphysiological signals. CDK activation requires its asso-
ciation with regulatory subunits called cyclins, as well as 2 to 5 after BCR stimulation. As shown in Figure 1E,
control littermates showed peak [3H]thymidine incorpo-the phosphorylation of CDK proteins in the assembled
complexes by CDK-activating kinase (CAK) (Sherr, 1994; ration on days 3 and 4, whereas proliferation in the
transgenic mice was inhibited throughout, decreasingMorgan, 1995). Activation of the inactive 120 kDa cyclin±
CDK complexes requires the dephosphorylation of CDK gradually to a negligible level on day 5. These data indi-
cate that the overexpression of mel-18 actively sup-proteins by CDC25A phosphatase (Galaktionov et al.,
1995). Each phase of the cell cycle is characterized by presses the cell proliferation mediated by BCR signaling
but does not delay the response. In order to confirm theexpressions of unique profiles of cyclin±CDK com-
plexes. In mammalian cells, progression through G1 is above results, we purified splenic small resting B cells
on a Percoll gradient and obtained the same results asregulated by the activity of D-type cyclins and cyclin E,
which associate with the CDK4/6 and CDK2 subunits, shown in Figures 1D and 1E (data not shown). The data
clearly demonstrate that the suppression of cell prolifer-respectively, whereas subsequent transitions through
the cell cycle require cyclin A-CDK2, cyclin A-CDC2, ation is due to a defect in the B lymphocytes and that this
defect relates directly to the overexpression of mel-18.and cyclin B-CDC2. It has been shown that the transcrip-
tional activation of immediate early (IE) genes contrib-
utes to the control of the cell cycle in response to various Overexpression of mel-18 Arrests the Cell Cycle
extracellular stimuli. For instance, c-myc has been re- between G1 and S Phase
ported to positively regulate cdc25a expression. Molec- There are at least two possibilities for this suppression
ular analysis in mel-18 transgenic mice revealed that of proliferation. One is that the decreased [3H]thymidine
the downregulation of cyclins D2 and E; CDK4, -6, and incorporation simply reflects the reduction in total cell
-7; and CDC25A causes impairment of the activities of number. This means that the overexpression of mel-18
cyclin±CDK complexes, resulting in hypo- or nonphos- induces cell death. The other is that the overexpression
phorylation of the retinoblastoma protein. In contrast, of mel-18 causes cell cycle arrest, resulting in the de-
the upregulation of c-Myc, CDC25, and CDC2 kinase crease in [3H]thymidine incorporation. To distinguish be-
activity results in the augmentation of the B cell prolif- tween these possibilities, we examined cell viability in
eration in mel-18-deficient mice. Thus, we propose the same samples used for the proliferation assay in
that mel-18 negatively regulates cell cycle progression Figure 1. As shown in Figure 2A, there was no difference
through a cascade leading to c-myc and then to cdc25a. in viability among the samples during cell culture up
to day 3. Thus, the data clearly support the second
possibility, namely, that the overexpression of mel-18Results
induces cell cycle arrest. To prove this, cell cycle distri-
butions were assessed at various times after stimulationOverexpression of mel-18 Prevents the Proliferation
by incorporation of bromodeoxyuridine (BrdU) followedof Mature B Cells upon B Cell
by bivariate flow cytometric analysis. As demonstratedReceptor Stimulation
in Figure 2B, 23.6% of cells from control mice enteredTo understand the function of mel-18 in the growth of
S phase after BCR stimulation, whereas only 2.4% oflymphoid cells, we generated mel-18 transgenic mice.
the mel-18-overexpressing cells were in S phase. ThisA 1.2 kb fragment of mel-18 cDNA containing an open
result indicates that for mel-18-overexpressing cells, thereading frame was introduced downstream of the IFN-
rate of entry into S phase is about one-tenth that ofinducible Mx promoter, and the construct was microin-
control cells. This 90% suppression in mel-18 transgenicjected into C57BL/6 fertilized eggs (Figure 1A). Three
mice is in good agreement with the result of the prolifera-independent lines were established; line 23 was highly
tion assay. The data therefore indicate that the overex-inducible by IFN (Figures 1B and 1C) and line 26 was
pression of mel-18 prevents the cell cycle from enteringconstitutive due to the context of the integration site.
S phase.Although the IFN-inducible promoter is very useful for
analyzing many biological systems, it is very difficult to
rule out the possibility that the effect on cell growth in our Overexpression of mel-18 Downregulates c-myc
but Not c-fos Expressiontransgenic mice will be the cumulative effect of genes
induced by both IFN treatment and mel-18 overexpres- Several explanations can be considered for the cell cycle
arrest caused by the overexpression of mel-18. How-sion. Thus, we decided to use line 26 for further experi-
ments. (We obtained the same results with inducible ever, considering that the level of expression of IE genes
(namely, c-myc and c-fos) is crucial to the cell cycle,line 23 in all following experiments [data not shown; see
Discussion].) especially in the transition from G0 to S phase, and that
we previously found the putative Mel-18 binding site toWe first performed a cell proliferation assay to deter-
mine whether the overexpression of mel-18 has any lie on the c-myc promoter region, we first addressed
the possibility that mel-18 regulates the cell cycle byeffect on the proliferation of mature B lymphocytes.
Splenic B cells were stimulated with anti-IgM or bacterial controlling IE gene expression (Heikkila et al., 1987;
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Roussel et al., 1991; Jansen-Durr et al., 1993; Hoang et
al., 1994; Barone and Courtneidge, 1995; Galaktionov
et al., 1995, 1996; Kanno et al., 1995; Morgan, 1995;
Steiner et al., 1995). We studied the levels of c-myc and
c-fos expression after BCR stimulation in normal and
transgenic mice.
As shown in Figures 2C and 2D, the stimulation of
normal B cells with anti-IgM results in increased levels
of mel-18 mRNA as well as c-fos and c-myc mRNAs.
The induction pattern of mel-18 mRNA is almost the
same as that of c-myc. The expression of mel-18 and
c-myc mRNAs reachs a maximum at 1 hr and is gradually
downregulated throughout G1 phase. The c-fos mRNA
is induced rapidly, reaching a maximum within 30 min,
and then decreases rapidly. This result suggests that
mel-18 can be categorized as an IE gene (Hasegawa et
al., 1998).
Next we compared the levels of c-myc and c-fos ex-
pression between normal and transgenic mice. Small
resting B cells obtained from both normal and transgenic
mice were treated with anti-IgM and subsequently ex-
amined for the expression of c-myc and c-fos. As shown
in Figures 2C and 2D, the initial 0 hr expression levels
of both c-myc and c-fos are the same as in control mice.
However, only c-myc expression is downregulated in
transgenic mice after BCR stimulation, while c-fos ex-
pression is essentially the same as in control mice.
These results suggest the presence of a negative regula-
tory pathway from mel-18 to c-myc during B cell activa-
tion to control cell proliferation. The results also indicate
that c-fos resides in a different pathway from c-myc
upon BCR stimulation in terms of its regulation by
mel-18.
Evidence for a Genetic Interaction
between mel-18 and c-myc
To test this possibility, we examined whether the en-
forced expression of c-myc in mel-18 transgenic mice
rescues the proliferation defect of B cells. We crossed
mel-18 transgenic mice with c-myc transgenic mice and
performed the proliferation assay after anti-IgM stimula-
tion. As shown in Figure 2E, the c-myc transgene alone
has no effect on BCR stimulation; however, in two inde-
pendent lines of double-transgenic mice, complete re-
covery of proliferation was observed compared with
mel-18 transgenic mice. Furthermore, in the double-
transgenic mice, 25.3% of the cells entered in S phase as
Figure 1. Cell Proliferation Is Specifically Inhibited in mel-18
Transgenic Mice upon B Cell Receptor Cross-Linking with Anti-IgM
(A) The construct of Mx-mel-18 transgenic mice. A 1.2 kb fragment (C) Northern blot experiment to analyze IFN inducibility in spleen
of the mouse mel-18 cDNA fragment was cloned into the BamHI cells of Mx-mel-18 transgenic mice. To determine whether the Mx
site of pGEM4Z containing a 1.7 kb fragment of IFN-inducible mouse promoter is inducible in transgenic mice, spleen cells from three
Mx promoter and a 2.2 kb genomic fragment of the human growth transgene lines and C57BL/6 mice were cultured in vitro with (lanes
hormone coding region and polyadenylation site (pGEM4Z-Mx-mel- 2, 4, 6, and 8) or without (lanes 1, 3, 5, and 7) 100 U/ml IFN for 4
18-hGH). hr. Northern blot analysis was performed with mel-18 cDNA as a
(B) Southern blot analysis on the founders of Mx-mel-18 transgenic probe using 20 mg of total RNA isolated from the cells. The mem-
mice. The 5.1 kb EcoRI fragment of pGEM4Z-Mx-mel-18-hGH was brane was rehybridized with G3PDH probe to verify equivalent load-
microinjected into C57BL/6 fertilized eggs, which were implanted ing of the RNA samples onto the lanes.
into foster mothers. The resulting progeny were screened for inte- (D and E) Proliferative response of splenic B cells. (D) Proliferation
gration of the mel-18 transgenes by Southern blot analysis on tail assays were performed with splenic B cells from control and mel-
DNA. Three independent lines were established, 9, 23, and 26, and 18 transgenic mice stimulated with anti-IgM or LPS on day 3. (E)
were used for further experiments. The 9 founder contained only Kinetics of the proliferative response after anti-IgM stimulation. The
1.91 copies of the transgene, but the 23 founder had almost 30 assay was performed with a saturating dose (40 mg/ml) of anti-IgM
copies. and followed to day 5 of culture.
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measured by BrdU incorporation (Figure 2B), indicating
that the cell cycle arrest by mel-18 overexpression is
recovered by the enforced expression of c-myc. These
results clearly demonstrate that c-myc is a downstream
target of mel-18.
The Presence of a Mel-18-Responsive Region
in the c-myc Promoter
We next investigated whether the mouse c-myc pro-
moter region is responsive to Mel-18 by performing tran-
sient transfections with a mel-18 expression vector,
pcD3-mel-18, and the pmyc CAT reporter construct con-
taining a 4.2 kb upstream fragment of the mouse c-myc
gene, including the P1 and P2 promoters. As shown in
Figure 3B, we observed transcriptional repression only
for the combination of mel-18 expression vector and
pmyc-CAT reporter plasmid. In this combination, the
increase in the amount of Mel-18 results in a decrease
in CAT activity (Figure 3B). The expression of Mel-18
does not affect the activity of either the SV40 promoter
(Figure 3B) or the HSV-tk minimal promoter (data not
shown). To confirm these observations, we constructed
several deletion mutants of the pmyc-CAT reporter plas-
mid (pmyc-CATD1, -D2, and -D3 [Figure 3A]). Deletions
in the most distal region (pmyc-CATD1) have no effects
on the repression of c-myc promoter activity; however,
further deletions (pmyc-CATD2) or the deletion of only
the 0.8 kb region (pmyc-CATD3), the difference between
pmyc-CATD1 and -D2, abolish repression (Figure 3C).
The data clearly indicate the presence of a Mel-18-
responsive region in the c-myc promoter. Sequence
analysis revealed the presence of one copy of a 59-GAC
TNGACT-39 sequence and four copies of a 59-GACT-39
sequence with various spacings within the 0.8 kb region
of the c-myc promoter (data not shown). Interestingly,
Bmi-1, which is closely related to Mel-18, sometimes
enhances c-myc promoter activity (Figure 3B), indicat-
ing that this protein might have an opposite function on
the c-myc promoter.
The cells were then stained with anti-BrdU-FITC and counterstained
with propidium iodide (PI). The boxes indicate S phase cells, and
the percentages of total cells in S phase of the cycle for littermate
controls and transgenic mice are indicated. In each analysis, 1 3
104 cells were examined.
(C) Expressions of mel-18, c-myc, and c-fos in small resting B cells
from normal and transgenic mice after BCR stimulation. The mRNA
expression level was analyzed on mel-18, c-myc, and c-fos in small
resting B cells from normal and transgenic mice after BCR stimula-
tion. RNA was extracted at the indicated times after stimulation,
and Northern blot analysis was performed on 20 mg of total RNA
with the indicated probes. Splenic small resting B cells from
Figure 2. Overexpression of mel-18 Arrests the Cell Cycle of B Cells transgenic mice at a concentration of 1 3 107/ml were stimulated
before the Entrance into S-phase and Can Be Rescued by Enforced with anti-IgM for 0±24 hr. G3PDH was used as an internal control.
Expression of c-myc (D) Graphic presentation of the kinetics of c-myc and c-fos mRNA
(A) The viability of small resting B cells after anti-IgM stimulation. induction in control and transgenic mice. The hybridization signals
To determine viability, B cells were cultured with 20 mg/ml anti-IgM were quantitated and normalized to the G3PDH signals. The plotted
at a concentration of 2 3 105 cells/ml for 1±3 days, stained with values for mel-18 transgenic mice were adjusted relative to the
trypan blue, and counted with a hemocytometer. maximum levels for control mice, taken as 100%. The experiment
(B) mel-18 overexpression prevents the cell cycle from entering S was repeated at least three times with independent preparations of
phase, and enforced expression of c-myc recovers the cells from stimulated cells.
G1 arrest. Flow cytometric analysis was performed on small resting (E) The proliferative response was assayed with anti-IgM (40 mg/
B cells from control littermates, mel-18 transgenic mice, and mel- ml) and [3H]thymidine using splenic B cells from normal, mel-18
18/c-myc double-transgenic mice after BCR stimulation with anti- transgenic, c-myc transgenic, and mel-18/c-myc double-transgenic
IgM. B cells from the various mice were incubated for 48 hr with mice. The proliferation assay was as described in the legend to
anti-IgM, and the cells were pulse-labeled in 10 mM BrdU for 6 hr. Figure 1.
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The Overexpression of mel-18 Causes Impaired
Kinase Activities of Cyclin±CDK Complexes,
Resulting in the Downregulation of Rb
Protein Hyperphosphorylation
To further understand the molecular mechanisms for
the cell cycle arrest caused by the overexpression of
mel-18 after BCR stimulation, we analyzed the expres-
sion and activities of cell cycle±related proteins. We first
focused our analysis on the hyperphosphorylation of Rb
proteins because this is the best indicator for assessing
the G1 to S phase transition. In control mice, the hyper-
phosphorylated form of the Rb protein appears at (or
before) 24 hr and remains present 48 hr after BCR stimu-
lation. However, in transgenic mice, the hyperphosphor-
ylated form of the Rb protein is barely detectable even
48 hr after stimulation, although the same amount of
hypophosphorylated or nonphosphorylated Rb protein
is present (Figure 4A). Since an impairment in Rb hyper-
phosphorylation is usually interpreted as a decrease in
the activities of cyclin-dependent kinases such as CDK2,
CDK4, and CDK6, we then compared these three kinase
activities in extracts of small resting B cells from control
and transgenic mice at different times. Surprisingly, all
three kinase activities were severely downregulated in
the transgenic mice (Figure 4B).
Since c-myc has been reported to positively regulate
cdc25a expression (Galaktionov et al., 1996), we first
analyzed the amounts of this protein to understand the
mechanisms for the impairment of CDK kinase activities.
As expected, the CDC25A protein is clearly downregu-
lated in transgenic mice (Figure 4C). The results demon-
strate that mel-18 is linked with cell cycle regulation
through a pathway leading to c-myc and then to cdc25a
(see Discussion).
We also analyzed the expressions of other cell cycle±
related proteins to explain the downregulation of cyclin-
dependent kinases. First, we examined the amounts of
G1 cyclins and CDK kinases. Among G1 cyclins, the
levels of cyclins A, D2, and E are greatly decreased in
mel-18 transgenic mice (Figure 4C). The level of cyclin
D3 is not affected, and cyclin D1 is undetectable in B
cells (data not shown). As for CDK proteins, CDK4 and
CDK6 are downregulated, while CDK2 is not (Figure 4C;
data not shown).
Next, we examined the amounts of cyclin H and CDK7
proteins, which together form a cyclin-associated kinase,
CAK. Again, the protein level of CDK7 kinase is severely
Figure 3. Evidence for the Presence of a Mel-18-Responsive Region downregulated to almost undetectable levels in trans-
in the c-myc Promoter genic mice compared with control mice (Figure 4C).
(A) Schematic representation of the expression vectors pcDNA3, Then, we examined the protein levels of all known CDK
pcD3-Mel-18, and pcD3-bmi-1, as well as the reporter plasmids inhibitors, namely, p15INK4b, p16INK4a, p18INK4c, p19INK4d,
pCAT-Basic, pSV40-CAT, and pmyc-CAT series.
p21Cip1/Waf1, p27Kip1, and p57Kip2. p21Cip1/Waf1 was the only(B) Graphical presentation of the repression of CAT activity by co-
upregulated CDK inhibitor to explain cell cycle arrest.transfection with the mel-18 expression vector and the CAT reporter
We also found the downregulation of p19INK4d and p27Kip1plasmid containing the c-myc promoter. The relative activity of each
reporter construct in the presence (1) or absence (2) of expression at the protein level (Figure 4C; data not shown).
vector (3 mg, left panel) as well as three different doses of vector Considering these results together, mel-18 appears
(0.3, 1.0, and 3.0 mg; right panel) are shown as percentages, where to affect the expression of multiple proteins linked to
the pSV40-CAT reporter plasmid containing the SV40 promoter is the activation of cyclin±CDK complexes, namely, G1taken as 100%.
cyclins (cyclins D2 and E), CDKs (CDK4 and CDK6),(C) Graphical presentation of the repression of CAT activity by co-
CAK (CDK7), CDC25A, and CDKI (p21Cip1/Waf1). It is nottransfection with mel-18 expression vector and the CAT reporter
plasmid with c-myc promoter deletion series. presently clear that mel-18 regulates the expression of
these proteins other than CDC25A and cyclin E through
a pathway involving c-myc.
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A Lack of mel-18 Accelerates Proliferation
Even in the Absence of BCR Stimulation
To confirm that the results in transgenic mice are not
side effects of the ectopic expression of mel-18, we
analyzed mel-18-deficient mice. The results of the prolif-
eration assay with splenic small resting B cells showed
[3H]thymidine incorporation to be accelerated even with-
out BCR stimulation in mel-18-deficient mice and the
maximum level of incorporation to reach nearly the same
level as that of normal littermates (Figure 5A). Further-
more, the c-Myc, CDC25A, and CDC25B proteins are
overexpressed and the activities of CDK2 and CDC2 are
upregulated in mel-18-deficient splenic B cells (Figures
5B and 5C). These results demonstrate that mel-18 is
normally linked with cell cycle regulation through a path-
way leading to c-myc.
Discussion
Identification of a Pathway of mel-18 Regulating
Cell Cycle Progression upon
B Cell Activation
In this study, we show that overexpression of mel-18
arrests the cell cycle of mature B cells before entry into
S phase after BCR stimulation and that the arrest is
accompanied by the downregulation of c-myc in both
constitutive and inducible mel-18 transgenic mice (line
26 and line 23, respectively) (this study; data not shown).
This cell cycle arrest is rescued by the enforced expres-
sion of c-myc in mel-18/c-myc double-transgenic mice.
Furthermore, cell proliferation and c-Myc expression are
accelerated in mel-18-deficient mature B cells even in
the absence of BCR stimulation. Therefore, we provide
novel evidence that a mammalian PcG gene, mel-18,
negatively regulates the cell cycle progression of B cells
by controlling c-myc expression. This is in good agree-
ment with our previous report that the blockage of en-
dogenous mel-18 expression by anti-sense mel-18 RNA
induces increased levels of c-myc expression, resulting
in tumorigenesis in NIH 3T3 cell (Kanno et al., 1995). It
has been thought that c-Myc exerts its mitogenic effect
by transcriptional control of cell cycle related±gene ex-
pression, resulting in the regulation of Rb protein phos-
phorylation (Jansen-Durr et al., 1993; Jiang, 1993; Han-
son et al., 1994; Hoang et al., 1994; Galaktionov et al.,
Figure 4. The Overexpression of mel-18 Downregulates Cell Cycle 1996).
Machinery Analysis of cell cycle±related proteins in mel-18 tans-
(A) Amounts of the hypophosphorylated and hyperphosphorylated genic mice revealed that the downregulation of cyclin-
forms of Rb proteins in control and transgenic B cells after BCR dependent kinase activities, CDK2, CDK4, and CDK6
stimulation.
results in hypo- or nonphosphorylation of the Rb protein.(B) The activity levels of CDK2, CDK4, and CDK6 kinases in control
On the other hand, the activities of CDK2 and CDC2and transgenic B cells at the indicated hours after BCR stimulation.
are upregulated in mel-18-deficient splenic B cells. TheHistone H1 (for CDK2) and GST±pRb fusion proteins (for CDK4 and
CDK6) were used as kinase substrates. Recombinant cyclin±CDK activation of the cyclin±CDK complex is known to be
protein complexes purified from baculovirus expression systems controlled by at least two pathways (Jansen-Durr et al.,
were used as positive controls. 1993; Jiang et al., 1993; Hanson et al., 1994; Hoang
(C) Protein expression levels of cyclins, CDKs, CDC25A, and CDKIs.
et al., 1994; Sherr, 1994; Morgan, 1995; Steiner et al.,Whole-cell extracts were prepared from B cells at the indicated
1995; Galaktionov et al., 1995, 1996). The first pathwaytimes after BCR stimulation, as described in Experimental Proce-
consists of two steps: (1) the release of the 120 kDadures, and the amounts of cell cycle molecules were analyzed by
Western blotting. These data were in good agreement with the re- cyclin±CDK complex from a 250 kDa inactive complex
cent report (Solvason et al., 1996). dependent on the expression of c-myc, and (2) the de-
phosphorylation of the CDK protein within the 120 kDa
inactive complex at Tyr-14 and Thr-15 mediated by
Cell Cycle Regulation by PcG Gene mel-18
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Figure 6. Cascade Model Proposed for Cell Cycle Control by PcG
Genes
This model represents a signal cascade from a membrane receptor
(BCR) to the cell cycle machinery via c-myc and mel-18. These
cascades might be positioned downstream of Src family kinases
associated with the receptor in lymphocytes. mel-18 negatively reg-
ulates the expression of c-myc, and c-myc positively regulates the
expression of mel-18 (M. K., data not shown). PcG genes are also
categorized as IE genes (Hasegawa et al., 1998).
mice and the upregulation of CDC25A and -B in mel-
18-deficient mice. A recent report describes cdc25a and
cdc25b as direct target genes of the c-Myc protein (Ga-Figure 5. Augmentation of B Cell Proliferation in mel-18 Knockout
Mice Even without BCR Stimulation Due to the Upregulation of laktionov et al., 1996). Therefore, we provide evidence
CDC2/CDK2 Activity that mel-18 negatively regulates the cell cycle progres-
(A) The proliferative response was assayed with anti-IgM and sion of B cells through a cascade leading to c-myc and
[3H]thymidine using splenic B cells from normal, mel-18 transgenic, then to cdc25a/b by controlling the equilibrium between
and mel-18 knockout (KO) mice. Assay conditions were as described the active and inactive forms of the 120 kDa cyclin±CDK
in the legend to Figure 1 and Experimental Procedures.
complex (Figure 6). We think that the equilibrium be-(B) Protein expression levels of c-Myc, CDC25A, and CDC25B in
tween the 250 kDa and 120 kDa complexes might alsocontrol and mel-18 KO mice. Whole-cell extracts were prepared
from B cells at the indicated times after BCR stimulation, as de- be affected by the downregulation of c-myc caused by
scribed in Experimental Procedures, and the amounts of cell cycle the overexpression of mel-18.
molecules were analyzed by Western blotting. Analysis of the second pathway also revealed the
(C) The activity of CDK2 and CDC2 kinases in control and KO mouse downregulation of several cell cycle molecules, namely,
B cells at the indicated times after BCR stimulation. Histone H1 was
cyclin D2, cyclin E, CDK4, and CDK6 proteins in mel-used as a kinase substrate. Assay conditions were the same as
18 transgenic mice. The impaired activity of the cyclinE/described in the legend to Figure 4B.
CDK2 kinase might be explained by the downregulation
of the cyclin E protein. However, we do not know at
present whether this severe downregulation is regulatedCDC25A phosphatase. The second pathway regulates
the synthesis and assembly of cyclins and CDK mole- directly by mel-18 or via control of another transcription
factor such as E2F, etc. (Ohtani et al., 1995; DeGregoricules to form cyclin±CDK complexes. The activities of
the assembled complexes are further regulated posi- et al., 1995; Leone et al., 1997, 1998; Nevins et al., 1997).
tively by the phosphorylation of the CDK protein by
the CDK-activating kinase CAK and negatively by CDK Diverse Function of mel-18 in Lymphoid Cell
Proliferation and Maturationinhibitors.
Analysis of the first pathway reveals the severe down- In this paper we describe mel-18 as a negative regulator
of proliferation linked with the BCR-mediated activationregulation of CDC25A expression in mel-18 transgenic
Immunity
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The resulting progeny were screened for integration of mel-18of mature B cells. The overexpression of mel-18 pre-
transgenes by Southern blot analysis on tail DNA and maintainedvents proliferation after BCR stimulation, and the loss
by mating with C57BL/6 mice. The transgenic mice used in thisof mel-18 causes an acceleration of proliferation even
study were 6±8 weeks of age and appeared healthy. mel-18-deficient
without any stimulation in mature B cells. These results mice have already been reported elsewhere (Akasaka et al., 1996).
seem to be in conflict with our previous finding that a Mx-c-myc transgenic mice were a kind gift from Dr. T. Ishibashi,
Chiba University.lack of mel-18 results in the impaired mitotic response
of immature B and T cells upon IL-7 stimulation (Akasaka
et al., 1997). However, we propose the possibility that Proliferation Assays
these contradictory observations can be explained if the Splenic B cells were isolated by anti-Thy1 and complement treat-
ment by the standard method (Coligan et al., 1994). Small restingfunctions of mel-18 required for lymphocyte proliferation
B cells were isolated from mouse spleens by the standard procedurediffer among signal transduction pathways. We hypoth-
(Coligan et al., 1994) on a discontinuous Percoll gradient (Pharmacia,esize that mel-18 works as a positive regulator for prolif-
Uppsala, Sweden). Bulk splenic cells (1 3 105) or purified small
eration mediated by cytokine receptors (IL-7R) and their resting B cells (2 3 105) were added to each well of a 96-well microti-
downstream molecules such as JAK3/STAT5. In con- ter plate in a final volume of 200 ml RPMI1640 (GIBCO BRL, Gaithers-
trast, mel-18 may act as a negative regulator for prolifer- burg, MD) supplemented with 10% FCS and 100 mM 2ME. The cells
were then cultured at 378C for 12 hr under 5% CO2. A goat anti-ation triggered by antigen receptors (BCR/TCR) and
IgM (m chain specific, Jackson ImmunoResearch Laboratories, Westtheir downstream molecules such as lyn, fyn, lck/ras,
Grove, PA) or LPS (Difco, Detroit, MI) was then added at 0±40 mg/ml,MAPK/Rel, and NF-kB. Recent reports suggested that
and the plates were incubated for a further 2±5 days. [3H]thymidine (1
the essential function of IL-7R signaling in lymphocyte
mCi) was added to each well 6 hr before the cells were harvested
development must be to promote cell survival in imma- and the radioactivity counted. All results are expressed as mean 6
ture lymphocytes, since the enforced expression of the SD of triplicate cultures. All experiments were repeated at least three
times, and the results of a representative experiment are shown.anti-apoptotic protein Bcl-2 rescues T lymphopoiesis in
IL-7R-deficient mice (Akashi et al., 1997; Maraskovsky
et al., 1997). We recently found that the loss of mel-18 Northern and Southern Blot Analysis
Total RNA was extracted from splenic small resting B cells usingalters the expression patterns of Bcl-2 family proteins,
TRIzol reagent (GIBCO BRL, Gaithersburg, MD). RNA (20 mg) wasresulting in an elevated sensitivity of lymphocytes to
subjected to Northern blot analysis by standard procedures (Ausu-death signals (M. K. et al., unpublished data). Consider-
bel et al., 1993). The following cDNA probes were used: mel-18, aing these observations, it is likely that upon IL-7R signal-
1.2 kb BamHI fragment containing the open reading frame; c-myc,
ing, mel-18 positively regulates the maintenance of via- a 1.2 kb fragment containing exons 2 and 3 of the mouse c-myc
bility of immature lymphocytes in a Bcl-2-dependent gene ; c-fos, a 0.8 kb fragment of exon 4; and G3PDH, a 472 bp
fragment. The signals were quantitated with an image analyzermanner. On the other hand, a recent report demon-
(BAS2000 [Fuji Photo Films Corporation, Tokyo, Japan]) and normal-strated that the enforced expression of Bcl-2 does not
ized to G3PDH. The extraction of mouse tail DNA and Southernpromote survival or the differentiation of T cells in mutant
hybridization were performed by standard procedures (Ausubel etrag-12/2 mice lacking antigen receptor molecules (Mara-
al., 1993). BamHI digests were hybridized with the 1.2 kb BamHI
skovsky et al., 1997). Upon Bcl-2-insensitive antigen fragment of the mel-18 cDNA.
receptor signaling, mel-18 may negatively regulate the
proliferation of mature lymphocytes by controlling the
Flow Cytometric Cell Cycle Analysis
cell cycle machinery via c-myc. The other possibility, Cell cycle distribution was analyzed by flow cytometry according
however, that the functions of mel-18 differ among the to established procedures (Yin et al., 1992). Small resting B cells
various stages of lymphocyte, cannot be excluded at were incubated for 48 hr with 20 mg/ml anti-IgM. The cells were
then exposed to 10 mM BrdU (Sigma, St. Louis, MO) for 6 hr, har-this time.
vested, and fixed with 70% ethanol. The cells were further treated
with 0.1 M HCl containing 0.5% Triton X-100 to extract histones,
Concluding Remarks then boiled and rapidly cooled on ice to denature the DNA. The
We demonstrate that a mammalian PcG gene, mel-18, cells were then stained with anti-BrdU-FITC (Boehringer-Mannheim,
Mannheim, Germany) and counterstained with 50 mg/ml propidiumregulates the cell cycle progression of lymphocytes in
iodide (PI) in 0.1% sodium citrate (pH 8.3) containing 2 mg/ml RNaseresponse to an extracellular signal mediated by an anti-
for 30 min on ice. Samples were analyzed by FACSCalibur (Bectongen receptor. Since mel-18 is expressed almost ubiqui-
Dickinson, San Jose, CA).tously in various tissues (Tagawa et al., 1990; Ishida et
al., 1993; M. K., unpublished data), the system is likely to
Western Blot Analysisbe important in many other biological systems. Further
Whole-cell lysates were made with cells from 3.5 cm dishes asstudies are necessary to obtain a clearer understanding
described previously (Hanson et al., 1994). Protein in the lysates
of PcG gene cascades in other biological systems. was assayed using a Micro Bicinchroninic Acid (BCA) Protein Assay
Kit (Pierce, Rockford, IL). Equal amounts of protein (20 mg), as indi-
cated by the assay, were electrophoresed and the gel was stainedExperimental Procedures
with Coomassie brilliant blue. The gel was inspected visually and,
if needed, fine adjustments were made to obtain appropriate vol-Mice
For generating mel-18 transgenic mice, a 1.2 kb BamHI±ApaI frag- umes for analysis by Western blotting. Western blotting was per-
formed by a standard method (Ausubel et al., 1993) using polyvinylment containing the open reading frame of mel-18 with the Kozak
sequence was cloned with BamHI adaptor into the BamHI site of a difluoride (PVDF) membranes (Millipore, Bedford, MA). The condi-
tions for quantitative electrotransfer were established in control ex-transgenic expression vector consisting of the mouse inducible Mx
promoter, human growth hormone genomic fragment, and pGEM4Z periments described previously (Hanson et al., 1994). All samples
were electrophoresed and blotted at least three separate times.(pGEM4Z-Mx-mel-18-hGH). The 5.1 kb EcoRI fragment of pGEM4Z-
mel-18-hGH containing the entire insert was microinjected into Membranes were probed sequentially with different antibodies, and
the blots were developed by enhanced chemiluminescence (ECL orC57BL/6 fertilized eggs, which were implanted into foster mothers.
Cell Cycle Regulation by PcG Gene mel-18
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ECL-Plus [Amersham, Buckinghamshire, United Kingdom]). Re- Akashi, K., Kondo, M., von Freeden-Jeffry, U., Murray, R., and Weiss-
man, I.L. (1997). Bcl-2 rescues T lymphopoiesis in interleukin-7 re-moval of antibodies prior to reprobing of the membranes was per-
ceptor-deficient mice. Cell 89, 1033±1041.formed according to the manufacturer's instructions (Amersham,
Buckinghamshire, United Kingdom). Alkema, M.J., Bronk, M., Verhoeven, E., Otte, A., van't Veer, L.J.,
The following antisera and monoclonal antibodies were used in Berns, A., and van Lohuizen, M. (1997). Identification of Bmi1-inter-
this study: polyclonal antibodies for Rb (14001A), p21Cip1/Waf1(13436E), acting proteins as constituents of a multimeric mammalian Poly-
and p27Kip1 (13231A or 15606E) (all from Pharmingen, San Diego, comb complex. Genes Dev. 11, 226±240.
CA); for cyclin A (C-19/sc-596), cyclin D2 (M-20/sc-593), cyclin D3 Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G.,
(H-292/sc-755 or C-16/sc-182), cyclin E (M-20/sc-481), cyclin H Smith, J.A., and Struhl, K. (1993). Current Protocols in Molecular
(FL323/sc-855), CDK2 (M2/sc-163), CDK4 (H303/sc-749), CDK6 Biology (New York: John Wiley and Sons).
(C-21/sc-177), CDK7 (FL-346/sc-856), CDC25A (144/sc-97), p18INK4c
Barone, M.V., and Courtneidge, S.A. (1995). Myc but not Fos rescue(N-20/sc-865), p19INK4d (M-167sc-1063), p21CIP1/Waf1 (C-19/sc-397),
of PDGF signaling block caused by kinase-inactive Src. Nature 378,and p57Kip2(E-17/sc-1037) (all from Santa Cruz Biotechnology, Santa
509±512.
Cruz, CA); and for p15INK4b and p16INK4a (both were kind gifts from
Bornemann, D., Miller, E., and Simon, J. (1996). The DrosophilaProf. C. Sherr). Monoclonal antibodies were for cyclin D1 (HD11/
Polycomb group gene sex comb on midleg (scm) encodes a zincsc-246, Santa Cruz Biotechnology, Santa Cruz, CA) and cyclin D1
finger protein with similarity to polyhomeotic protein. Development(clone 105/C20320), cyclin D3 (clone 11/C28620), CDK2 (clone 55/
122, 1621±1630.C18520), CDK4 (clone 97/C18720), and p27Kip1 (clone 57/K25020) (all
Brunk, B.P., Martin, E.C., and Adler, P.N. (1991). Drosophila genesfrom Transduction Laboratories, Lexington, KY).
posterior sex combs and suppressor two of zeste encodes proteins
with homology to the murine bmi-1 oncogene. Nature 353, 351±353.Immune Complex Kinase Assay
Cell extracts were prepared basically as described previously (Mat- Celniker, S.E., Sharma, S., Keelan, D.J., and Lewis, E.B. (1990). The
sushime et al., 1994). Briefly, cells were suspended at 1 3 106/ml molecular genetics of the bithorax complex of Drosophila. EMBO
in IP buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1 mM EDTA, 2.5 J. 9, 4277±4286.
mM EGTA, 1 mM dithiothreitol [DTT], 0.1% Tween-20) containing Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., and
10% glycerol, 10 mM b-glycerophosphate, 1 mM NaF, 0.1 mM so- Strober, W. (1994). Current Protocols in Immunology. (New York:
dium orthovanadate, and a proteinase inhibitor cocktail (50 mg/ml John Wiley and Sons).
of antipain, 2 mg/ml of aprotinin, 40 mg/ml of bestatin, 20 mg/ml of
Core, N., Bel, S., Gaunt, S.J., Aurrand-Lions, M., Pearce, J., Fisher,
chymostatin, 2 mg/ml of E-64, 0.5 mg/ml of leupeptin, 0.5 mg/ml of A., and Djabali, M. (1997). Altered cellular proliferation and meso-
Pefabloc, and 0.7 mg/ml of pepstatin [Boehringer-Mannheim, Mann- derm patterning in Polycomb-M33-deficient mice. Development
heim, Germany]) and then sonicated at 48C. Lysates were clarified 124, 721±729.
by centrifugation at 10,000 3 g for 5 min, and the supernatants
DeGregori, J., Kowalik, T., and Nevins, J.R. (1995). Cellular targetswere precipitated for 6 hr at 48C with protein A-Sepharose beads
for activation by the E2F1 transcription factor include DNA synthe-precoated with saturating amounts of various antibodies. Immuno-
sis- and G1/S-regulatory genes. Mol. Cell. Biol. 15, 4215±4224.precipitated proteins on the beads were washed four times with 1
Galaktionov, K., Jessus, C., and Beach, D. (1995). Raf1 interactionml of IP buffer and twice with 50 mM HEPES (pH 7.5) containing 1
with Cdc25 phosphatase ties mitogenic signal transduction to cellmM DTT. The beads were suspended in 30 ml of kinase buffer (50
cycle activation. Genes Dev. 9, 1046±1058.mM HEPES [pH7.5], 10 mM MgCl2, 1 mM DTT) containing substrate
(either 0.2 mg of soluble glutathione S-transferase±pRb fusion pro- Galaktionov, K., Chen, X., and Beach, D. (1996). Cdc25 cell-cycle
tein [a kind gift from Dr. Matsushime], or 1 mg of histone H1 [Boeh- phosphatase as a target of c-myc. Nature 382, 511±517.
ringer Mannheim, Mannheim, Germany]) as well as 2.5 mM EGTA, Hanson, K.D., Shichiri, M., Follansbee, M.R., and Sedivy, J.M. (1994).
10 mM b-glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM Effects of c-myc expression on cell cycle progression. Mol. Cell.
NaF, 20 mM ATP, and 10 mCi of [g-32P]ATP (6000 Ci/mmol; Amer- Biol. 14, 5748±5755.
sham, Buckinghamshire, United Kingdom). After incubation for 30 Haupt, Y., Bath, M.L., Harris, A.W., and Adams, J.M. (1993). bmi-1
min at 308C with occasional mixing, the samples were boiled in SDS transgene induces lymphomas and collaborates with myc in tumori-
sample buffer and separated by electrophoresis. Positive control genesis. Oncogene 8, 3161±3164.
samples, recombinant cyclin±CDK complexes from a baculovirus
Hasegawa, M., Tetsu, O., Kanno, R., Inoue, H., Ishihara, H., Kami-
expression system, were also kind gifts from Dr. Matsushime.
yasu, M., Taniguchi, M., and Kanno, M. (1998). Mammalian Poly-
comb group genes are categorized as new type of early response
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